Fairmount Funds Management’s Crescent Biopharma CBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$52.5M Buy
3,601,316
+853,450
+31% +$14.3M 3.3% 10
2026
Q2
$49.5M Hold
2,747,866
– – 3.27% 9
2026
Q1
$50.5M Hold
2,747,866
– – 3.65% 9
2025
Q4
$32.6M Buy
2,747,866
+1,360,000
+98% +$17.3M 2.48% 12
2025
Q3
$16.5M Hold
1,387,866
– – 1.48% 16
2025
Q2
$22.4M Buy
+1,387,866
New +$29.4M 2.9% 13

Other funds holding CBIO

Fairmount Funds Management's CBIO Position: Q3 2026 in Review

Fairmount Funds Management increased its Crescent Biopharma (CBIO) stake by 31% in Q3 2026, buying an estimated $14.3M and bringing the position to 3,601,316 shares worth $52.5M. The position accounts for 3.3% of the portfolio, ranked #10.

Fairmount Funds Management first reported a position in CBIO in Q2 2025 and has held it in 6 quarters since. 106 funds tracked by Wall St. Rank hold CBIO as of Q3 2026.

  • Fairmount Funds Management held 3,601,316 shares of Crescent Biopharma worth $52.5M as of Q3 2026.
  • Fairmount Funds Management bought 853,450 Crescent Biopharma shares in Q3 2026, an estimated $14.3M.
  • Crescent Biopharma made up 3.3% of Fairmount Funds Management's portfolio in Q3 2026, its #10 holding.
  • Fairmount Funds Management first reported a position in Crescent Biopharma in Q2 2025 and has held it in 6 quarters since.
  • 106 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2026.

Based on Fairmount Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.